Cisatracurium (free base)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412954

CAS#: 96946-41-7 (free base)

Description: Cisatracurium (free base) is an intermediate-duration, non-depolarising neuromuscular blocking agent for intravenous administration. Cisatracurium is indicated for use during surgical and other procedures and in intensive care in adults and children aged 1 month and over.

Chemical Structure

img
Cisatracurium (free base)
CAS# 96946-41-7 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 412954
Name: Cisatracurium (free base)
CAS#: 96946-41-7 (free base)
Chemical Formula: C53H72N2O122+
Exact Mass: 928.51
Molecular Weight: 929.160
Elemental Analysis: C, 68.51; H, 7.81; N, 3.01; O, 20.66

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Cisatracurium (free base), 96946-42-8 (besylate)

IUPAC/Chemical Name: (1R,1'R,2R,2'R)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium)

InChi Key: YXSLJKQTIDHPOT-LJCJQEJUSA-N

InChi Code: InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1

SMILES Code: COc1c(OC)cc(C[C@@H]2c3c(CC[N@@+]2(CCC(OCCCCCOC(CC[N@+]4(CCc5c([C@H]4Cc6cc(OC)c(OC)cc6)cc(OC)c(OC)c5)C)=O)=O)C)cc(OC)c(OC)c3)cc1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 929.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Strawbridge AD, Khanna NR, Hauser JM. Cisatracurium. 2020 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 30969664.

2: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Cisatracurium. 2020 Nov 16. PMID: 29999740.

3: Lim J, Cox J, Nguyen T, Arya R. Cisatracurium dosing in a patient with hyperthermia. Am J Health Syst Pharm. 2019 Jul 2;76(14):1029-1032. doi: 10.1093/ajhp/zxz098. PMID: 31361873.

4: Sottile PD, Kiser TH, Burnham EL, Ho PM, Allen RR, Vandivier RW, Moss M; Colorado Pulmonary Outcomes Research Group (CPOR). An Observational Study of the Efficacy of Cisatracurium Compared with Vecuronium in Patients with or at Risk for Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2018 Apr 1;197(7):897-904. doi: 10.1164/rccm.201706-1132OC. PMID: 29241014; PMCID: PMC6020402.

5: National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT, Brower RG, Ferguson ND, Ginde AA, Gong MN, Grissom CK, Gundel S, Hayden D, Hite RD, Hou PC, Hough CL, Iwashyna TJ, Khan A, Liu KD, Talmor D, Thompson BT, Ulysse CA, Yealy DM, Angus DC. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med. 2019 May 23;380(21):1997-2008. doi: 10.1056/NEJMoa1901686. Epub 2019 May 19. PMID: 31112383; PMCID: PMC6741345.

6: Che D, Rui L, Cao J, Wang J, Zhang Y, Ding Y, Zhao T, Ma P, An H, Gao Z, Zhang T. Cisatracurium induces mast cell activation and pseudo-allergic reactions via MRGPRX2. Int Immunopharmacol. 2018 Sep;62:244-250. doi: 10.1016/j.intimp.2018.07.020. Epub 2018 Jul 20. PMID: 30032049.

7: Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P, Lefrant JY, Guérin C, Prat G, Morange S, Roch A; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010 Sep 16;363(12):1107-16. doi: 10.1056/NEJMoa1005372. PMID: 20843245.

8: Ortiz JR, Percaz JA, Carrascosa F. Cisatracurio [Cisatracurium]. Rev Esp Anestesiol Reanim. 1998 Jun-Jul;45(6):242-7. Spanish. PMID: 9719722.

9: Merkel A, Massey K, Bellamy C, Miano T, Fuchs B, Candeloro C. Predictors of Cisatracurium Continuous Infusion Dose in Acute Respiratory Distress Syndrome. J Pharm Pract. 2019 Nov 18:897190019888103. doi: 10.1177/0897190019888103. Epub ahead of print. PMID: 31736402.

10: Szakmany T, Woodhouse T. Use of cisatracurium in critical care: a review of the literature. Minerva Anestesiol. 2015 Apr;81(4):450-60. Epub 2014 Apr 10. PMID: 24721895.